Sat, Jul 26, 2014, 5:22 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

ImmunoGen, Inc. Message Board

biotechbeagle 60 posts  |  Last Activity: 12 hours ago Member since: Feb 11, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biotechbeagle biotechbeagle 12 hours ago Flag

    Maybe Roche helping drive down IMGN Stock to acquire on the cheap, then drive Kadcyla with 100% ownership. GSK screwed HGSI with their Lupus drug in early launch driving the price down only to pick them up on the cheap.

  • Reply to

    hedge fund increases stake

    by bozedar1 Jul 24, 2014 3:26 PM
    biotechbeagle biotechbeagle Jul 24, 2014 6:03 PM Flag

    This suggests possible BOD shake up with their new 10% of influence.

    "Broadfin Capital reports 9.98% stake in Cardica Broadfin Capital has recently engaged, and intend to continue to engage, in discussions with the company’s management and board of directors regarding the composition of the Board, generally, and means to enhance stockholder value."

    I'm sure Broadfin sees possible catalysts just ahead such as Japan Microcutter Approval, Microcutter 45 exchange submission and possible ISRG DaVinci Microcutter. R&D surely has made progress since that original licensing deal.

  • Reply to

    Perjeta

    by slumdawg2011 Jul 24, 2014 10:08 AM
    biotechbeagle biotechbeagle Jul 24, 2014 10:19 AM Flag

    Kadcyla is Herceptin cannibalization where Perjeta is an add to existing correct?

  • Reply to

    PUMA Phase 3 Success

    by biotechbeagle Jul 23, 2014 10:58 AM
    biotechbeagle biotechbeagle Jul 23, 2014 1:42 PM Flag

    Slumdawg thanks for the quick analysis and facts! Much appreciated. Thanks for being a poster on this board, too quiet around here!

  • biotechbeagle by biotechbeagle Jul 23, 2014 10:58 AM Flag

    How does PUMA Her2 Breast Cancer Likely approval impact Kadcyla?

  • Reply to

    revenue from ovarian orphan drug status from FDA?

    by my_daddie Jul 15, 2014 3:29 PM
    biotechbeagle biotechbeagle Jul 18, 2014 11:54 AM Flag

    Much to your chagrin stock grants were handed to sr leadership. Dan gets 210k, while lambert, Johnston and Morris get 100k. Directors like O'Leary get 80k all at $10.79

  • Reply to

    revenue from ovarian orphan drug status from FDA?

    by my_daddie Jul 15, 2014 3:29 PM
    biotechbeagle biotechbeagle Jul 17, 2014 5:29 PM Flag

    Bio, I feel your pain and are also frustrated. How much of it is simply the steep challenges in science and especially oncology? I would be disappointed with the management team if we didn't have 17 clinical trials going on, 1 approval and 4 wholly owned with the who's who of oncology, had no focus and wasted money. If it was that bad, wouldn't also invite activists like Icahn and Ackerman? I feel we've been beat down much like HGSI after their Lupus approval then acquired by GSK. Things are being overly hyped with a negative slant.

    I find it very strange they didn't post the Orphan Designation News.

    This was from a seeking alpha article:

    "A near term catalyst for an Immunogen stock price jump comes from the possibility of it being acquired. Recently, the company's executives filed an 8K form. The 8K form outlined the compensatory arrangement and departure process of officers in the event of a merger or consolidation. Immunogen may be acquired at any time this year given that it sits on $211 million in cash with no debt and that a widely expected FDA approval of T-DM1 is right around the corner."

  • Reply to

    Stapler In Hospitals

    by cutiger1980 Jul 15, 2014 7:02 PM
    biotechbeagle biotechbeagle Jul 16, 2014 9:40 AM Flag

    Agreed! With Just Right getting out there also with there 5mm, they are both creating demand for less invasive staplers. CRDC is in a better position since Just Rights stapler really has no IP because it uses the "B" staple design and does not have the articulation of cardiac. They have sealing, which cardiac will also eventually have. With the ability to get down to 3mm with cardicas D staple, flex shaft, multi-fire etc they will have the most comprehensive product line. Questions is how far in the development will they get before being acquired. MLV did say they will be acquired once they complete development (may not mean approval) of their microcutter product line. Abbott has sold off their generic pharm rx business and stated they plan to go shopping for new medical devices. Can't expect Stryker to sit out of the autosuture market either. But I do not see one of the market leaders let this one get a way. It's with unequivocally the best IP available!

    Sentiment: Strong Buy

  • Reply to

    revenue from ovarian orphan drug status from FDA?

    by my_daddie Jul 15, 2014 3:29 PM
    biotechbeagle biotechbeagle Jul 15, 2014 9:29 PM Flag

    Shouldn't IMGN have had a press release on receiving FDA orphan status? Strange! Does it require an 8k filing?

  • Reply to

    Royalty stream kadcyla

    by gunter.strobel Jul 12, 2014 7:55 AM
    biotechbeagle biotechbeagle Jul 14, 2014 9:26 AM Flag

    We need to get that Morgan Stanley Bearish press release off the top of the yahoo page! Need some positive news as most recent.

    btw Love Germany! I head there every other year when the F1 Race is in Nurburgring stay in Colonge and spend rest of time in Garmish, Fussen.

  • If you're going to post info on non-CDRC info, please keep it to the space and make it good quality. Not pink sheet junk that trades under a penny!

  • REGN was knocked down by analyst stating they were losing 10% of Eylea sales per month to competition. Was knocked down all the way to $276, then we learn that Sanofi increased their stake and it's back up to $315 as takeover rumors persist. This bearish call is not justified and driven by an analyst agenda in my opinion.

    Sentiment: Strong Buy

  • Reply to

    Morgan Stanley report

    by bioimmunomabman Jul 1, 2014 8:59 AM
    biotechbeagle biotechbeagle Jul 1, 2014 3:43 PM Flag

    I think this MS Analyst has an agenda to drive the market valuation down to a potential acquirers liking. How can he value as he did when IMGN has a rare asset as one of the few true MAB manufactures, a successful ADC platform and all the top pharma names using their technology with a total of 17 shots on goal! Is Morgan Standley smarter than Roche, Novartis, Sanofi, Bayer, Amgen, Lilly and BioTest?

    Sentiment: Strong Buy

  • Reply to

    It's Been Awhile Since I've Checked In

    by golf.paul123 Jul 1, 2014 12:55 PM
    biotechbeagle biotechbeagle Jul 1, 2014 1:20 PM Flag

    IMGN is no penny stock, it's a real Biotech Company with great asset value. This MS Analyst has an agenda. You should have averaged down on IMGN, it will be back above your purchase price!

    Sentiment: Buy

  • in July-August. This agency has improved their review process and has committed to approvals within1 year of filing. Century, Cardica's Japan distributor filed last August. So this should be any day now.

    Sentiment: Strong Buy

  • biotechbeagle by biotechbeagle May 30, 2014 5:57 PM Flag

    Background: CoR is an anti-CD19 antibody maytansinoid conjugate. CD19 is expressed in the majority of B cell lymphomas. Phase I program showed clinical activity in pts with both indolent and aggressive lymphomas. Methods: Pts withCD19+ R/R DLBCL after at least one standard treatment including rituximab and not candidate for transplantation were eligible. Primary refractory pts were excluded. Biopsy was required at baseline. CoR 55 mg/m² was administered weekly for 4 weeks then bi-weekly until disease progression or other study discontinuation criteria. The primary objective was to demonstrate an overall response rate (ORR) of at least 20% following Cheson 2007 criteria. Tumor assessments were done every 12 weeks. Secondary objectives were: safety, pharmacokinetics (PK), duration of response (DOR), progression free and overall survival (PFS, OS). Assessment of correlation between biomarkers (BM) status and disease outcome was an exploratory objective. Results: 41 pts were evaluable. Median age was 71 (39:85), 53.7% were male; 92.7% had ECOG performance status 0-1. 31.7% had received ≥ 3 prior regimens for DLBCL. The ORR was 43.9% (90% CI: 30.6% to 57.9%, p-value 10%) all grades (gr) non-hematologic treatment-emergent adverse events (TEAEs) were nausea (23.0%), diarrhea (19.7%), fatigue and cough (18.0%), vomiting and decrease appetite (13.1%), asthenia, abdominal and back pain (11.5%). TEAEs led to treatment discontinuation in 4 pts. Only gr 1-2 eye disorders were reported, including 1 pt with unrelated gr 2 keratitis. Peripheral neuropathies were observed in 5 pts, all were gr 1-2. Hematological toxicity was moderate, with gr 3-4 neutropenia, thrombocytopenia and anemia in 26.4%, 9.9% and 6.6% pts respectively. PK assessment and investigations on BM expression are ongoing. Conclusions: CoR as single agent demonstrated significant activity in R/R DLBCL pts and reached its primary endpoint for ORR, with acceptable safety profile. Trial funded by Sanofi. Clinical trial information: NCT01472887.

    Sentiment: Hold

  • biotechbeagle by biotechbeagle May 30, 2014 5:50 PM Flag

    Background: IMGN529 is a CD37-targeting ADC comprising a CD37-binding antibody conjugated to the maytansinoid anti-mitotic, DM1. CD37 is present on the surface of normal and malignant B lymphocytes. In preclinical studies, IMGN529 exhibits potent antitumor activity against NHL cells via direct inhibition, effector function and delivery of the maytansinoid payload. Methods: Study objectives are: determine the maximum tolerated dose/recommended phase 2 dose of IMGN529 in adult patients (pts) with relapsed or refractory NHL, and evaluate safety, pharmacokinetics, pharmacodynamics, and evidence of preliminary efficacy. IMGN529 is given intravenously on Day (d) 1 of each 21d cycle (C). Results: To date, 22 pts have been enrolled across four dose levels ranging from 0.1 to 0.8 mg/kg. NHL subtypes enrolled: 10 Follicular lymphoma (FL), 7 Diffuse large B-cell (DLBCL), 5 other. A reduction in lymphocyte count seen early after dosing (d 2) in the majority of pts suggests a CD37-mediated reduction in lymphocytes. One pt with DLBCL treated at 0.4 mg/kg, and 1 pt with FL treated at 0.2 mg/kg achieved partial remission in C 3 and C 5 respectively. Dose limiting toxicities (DLTs) consisted of grade (G) 4 neutropenia 7 days (1pt) and G2 peripheral neuropathy (1pt) at 0.8 mg/kg and G3 febrile neutropenia (2 pts) at 0.4 mg/kg. Adverse events (AEs) of G3 or higher occurred in 8 pts; those reported in more than 1 pt were: neutropenia (5 pts) and febrile neutropenia (2pts). Four of these pts experienced transient, early onset (C1d2-4) G3 neutropenia which may be a manifestation of cytokine release. The protocol was amended to provide peri-infusional steroids as a prophylactic regimen and dose re-escalation is ongoing; 3 patients treated at 0.4 mg/kg have completed C 1 with no DLTs. Clinical trial enrollment is ongoing with additional data expected. Preclinical studies to investigate the mechanism of the transient neutropenia are underway. Conclusions: IMGN529, a CD37-targeting ADC, has demonstrated early evidence of clinical activity and has the potential to be a novel therapeutic for B-cell lymphoproliferative malignancies. Clinical trial information: 01534715.

    Sentiment: Hold

  • Reply to

    1.4 millions shares by 9:30

    by bemore4224 May 23, 2014 11:34 AM
    biotechbeagle biotechbeagle May 23, 2014 5:41 PM Flag

    This may be Broadfin Capital Healthcare Master Fund. They now own 9.4% per the May 22nd 13G filing.

    Sentiment: Strong Buy

  • Reply to

    1.4 millions shares by 9:30

    by bemore4224 May 23, 2014 11:34 AM
    biotechbeagle biotechbeagle May 23, 2014 5:22 PM Flag

    This was the 191,474 share times 100 or 1.9M shares total. Each share of Series A preferred stock is convertible into 100 shares of our common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series A preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of our common stock then issued and outstanding, unless the holder gives us at least 61 days prior notice of an intent to convert into shares of common stock that would cause the holder to own more than 9.98% of the total number of shares of our common stock then issued and outstanding.

    Sentiment: Strong Buy

  • Reply to

    CEO

    by lgg_lewis May 23, 2014 9:46 AM
    biotechbeagle biotechbeagle May 23, 2014 10:00 AM Flag

    CFO did at $0.95/share. 52,000 shares this am is a good start.

IMGN
10.63-0.26(-2.39%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.